Clinical trial
A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age
NCT00303069 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2005
- Completion date
- July 31, 2006
- Enrollment
- 124 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.